Walleye Capital’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.16M Buy
+17,500
New +$4.61M ﹤0.01% 1863
2026
Q2
– Sell
-2,500
Closed -$431K – 4798
2026
Q1
$431K Buy
2,500
+2,300
+1,150% +$426K ﹤0.01% 2779
2025
Q4
$39.9K Sell
200
-5,000
-96% -$907K ﹤0.01% 4134
2025
Q3
$814K Buy
5,200
+2,900
+126% +$461K ﹤0.01% 2254
2025
Q2
$349K Buy
2,300
+1,600
+229% +$213K ﹤0.01% 2936
2025
Q1
$105K Sell
700
-800
-53% -$134K ﹤0.01% 3596
2024
Q4
$277K Buy
1,500
+1,200
+400% +$231K ﹤0.01% 3487
2024
Q3
$59.1K Sell
300
-600
-67% -$125K ﹤0.01% 4588
2024
Q2
$186K Sell
900
-21,500
-96% -$4.87M ﹤0.01% 4357
2024
Q1
$6.07M Sell
22,400
-14,700
-40% -$3.51M 0.01% 1164
2023
Q4
$8.77M Sell
37,100
-1,700
-4% -$334K 0.02% 733
2023
Q3
$7.6M Buy
38,800
+20,400
+111% +$4.19M 0.02% 740
2023
Q2
$3.87M Buy
18,400
+9,800
+114% +$1.95M 0.01% 892
2023
Q1
$1.74M Buy
+8,600
New +$1.95M 0.03% 809
2022
Q4
– Sell
-1,100
Closed -$216K – 3258
2022
Q3
$216K Buy
+1,100
New +$237K ﹤0.01% 2055
2019
Q4
– Sell
-1,300
Closed -$172K – 1866
2019
Q3
$172K Sell
1,300
-600
-32% -$80.4K 0.01% 1255
2019
Q2
$270K Sell
1,900
-400
-17% -$54.3K 0.03% 789
2019
Q1
$334K Buy
+2,300
New +$302K 0.06% 552

Other funds holding CRL

Walleye Capital's CRL Position: Q3 2026 in Review

Walleye Capital opened a new position in Charles River Laboratories (CRL) in Q3 2026: 4,075 shares worth $1.2M. The stake represents ﹤0.01% of the portfolio and ranks #3290 among its holdings. This is a return to the name: Walleye Capital previously reported a position in CRL as recently as Q1 2026.

Walleye Capital first reported a position in CRL in Q1 2019 and has held it in 17 quarters since. The position peaked at $50.1M in Q4 2025. 639 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Walleye Capital held 4,075 shares of Charles River Laboratories worth $1.2M as of Q3 2026.
  • Charles River Laboratories was a new Walleye Capital position in Q3 2026.
  • Charles River Laboratories made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #3290 holding.
  • Walleye Capital first reported a position in Charles River Laboratories in Q1 2019 and has held it in 17 quarters since.
  • Walleye Capital's Charles River Laboratories position peaked at $50.1M in Q4 2025.
  • 639 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.